Osler, Hoskin & Harcourt LLP advised Inversago Pharma on the matter. On August 10, 2023, Inversago Pharma announced its business combination with Nova Nordisk for US$1.075...
Inversago Pharma’s $1.075 Billion Business Combination with Novo Nordisk
Inversago Pharma’s $70 Million Series C Financing
White & Case and Osler, Hoskin & Harcourt LLP advised Inversago Pharma Inc. on the deal, while Wilson Sonsini advised NEA. Inversago Pharma Inc., a clinical-stage...